Eckert & Ziegler building $9M PET plant in Poland; Novo Nordisk hires for U.S. manufacturing;

> Berlin-based Eckert & Ziegler, is building a €7 million ($9.3 million) plant in Warsaw, Poland, to manufacture cyclotron-based PET radiopharmaceuticals. Release

> Novo Nordisk ($NVO) is adding positions at its manufacturing plant in Clayton, NC, as part of a 15% expansion of operations in the U.S., which the company announced last week. Release

> Penn Pharma has added some new packaging lines as part of its £14m ($22.7 million) expansion of the Tradegar plant in South Wales. Story

> Authorities in Pakistan are continuing an investigation into whether epinephrine provided to some pharmaceutical companies there was used to make illegal drugs. Story

> API manufacturers often get noticed if they have difficulties with FDA inspections so Cambrex is letting everyone know that it passed an FDA inspection in February of its API plant in Charles City, IA. Item

> Bosch Packaging Technology has finalized the acquisition of the machinery business of Eisai, which includes pharmaceutical machinery and packaging materials. Item

> Never a big category for cargo theft in Mexico, FreightWatch International says there was only one reported pharmaceutical theft in Mexico during the first quarter of 2012. Report (reg. req.)

> Without specifying where, Ontario-based IGY Immune Technology & Life Sciences said it has acquired manufacturing "capabilities" near large-scale chicken egg producers to make IgY products from egg yolks. Item

> The American Red Cross has made a $9.6 million payment pegged to a consent decree from 2003. FDA notice
 

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.